Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2021 | Highlights from AD/PD: Donanemab & iADRS

Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, outlines the results presented from the Phase II TRAILBLAZER-ALZ study (NCT03367403) of donanemab in patients with early symptomatic Alzheimer’s disease (AD) as one of her key highlights from the AD/PD 2021 conference. Dr. Hendrix describes the novel Integrated Alzheimer’s Disease Rating Scale (iADRS) used in this study, which combines cognition and function into one endpoint in order to improve sensitivity to AD progression over time. She also discusses the benefits of using a range of other outcome measures and statistical tests in clinical trials to better evaluate the impact of AD therapies on overall disease. This interview took place during the AD/PD™ 2021 conference.